Total Payments
$866,043
2024 Payments
$13,456
Companies
53
Transactions
1,363
Medicare Patients
12,806
Medicare Billing
$711,262
Payment Breakdown by Category
Research$571,934 (66.0%)
Other$154,747 (17.9%)
Consulting$74,994 (8.7%)
Travel$35,935 (4.1%)
Food & Beverage$28,101 (3.2%)
Education$331.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $571,934 | 56 | 66.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $153,747 | 83 | 17.8% |
| Consulting Fee | $74,994 | 21 | 8.7% |
| Travel and Lodging | $35,935 | 90 | 4.1% |
| Food and Beverage | $28,101 | 1,106 | 3.2% |
| Honoraria | $1,000 | 1 | 0.1% |
| Education | $331.50 | 6 | 0.0% |
Payments by Type
Research
$571,934
56 transactions
General
$294,109
1,307 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $565,196 | 27 | $0 (2019) |
| Gilead Sciences, Inc. | $150,386 | 355 | $0 (2024) |
| ViiV Healthcare Company | $126,377 | 462 | $0 (2024) |
| Merck Sharp & Dohme LLC | $6,490 | 63 | $0 (2024) |
| ABBVIE INC. | $3,562 | 25 | $0 (2024) |
| Daiichi Sankyo Inc. | $2,920 | 10 | $0 (2017) |
| Allergan Inc. | $2,386 | 13 | $0 (2019) |
| Janssen Biotech, Inc. | $1,650 | 100 | $0 (2023) |
| Theratechnologies Inc. | $1,415 | 24 | $0 (2024) |
| EMD Serono, Inc. | $1,080 | 43 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,456 | 145 | Gilead Sciences, Inc. ($10,306) |
| 2023 | $21,966 | 138 | ViiV Healthcare Company ($17,058) |
| 2022 | $13,459 | 110 | ViiV Healthcare Company ($8,833) |
| 2021 | $20,598 | 118 | ViiV Healthcare Company ($17,639) |
| 2020 | $41,504 | 106 | ViiV Healthcare Company ($26,689) |
| 2019 | $85,732 | 243 | Gilead Sciences, Inc. ($39,523) |
| 2018 | $309,326 | 239 | Janssen Research & Development, LLC ($244,332) |
| 2017 | $360,003 | 264 | Janssen Research & Development, LLC ($299,483) |
All Payment Transactions
1,363 individual payment records from CMS Open Payments — Page 1 of 55
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug) | Food and Beverage | In-kind items and services | $25.78 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/13/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $28.95 | General |
| Category: HIV | ||||||
| 12/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $35.65 | General |
| 11/25/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $34.29 | General |
| Category: HIV | ||||||
| 11/21/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: PAIN | ||||||
| 11/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.08 | General |
| 11/19/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $34.21 | General |
| Category: HIV | ||||||
| 11/18/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: HIV | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $112.00 | General |
| 11/14/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $93.66 | General |
| 11/14/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $34.40 | General |
| 11/12/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $22.64 | General |
| Category: HIV | ||||||
| 11/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $28.13 | General |
| Category: PSYCHIATRY | ||||||
| 11/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.57 | General |
| 11/04/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/31/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $34.62 | General |
| Category: HIV | ||||||
| 10/30/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: HIV | ||||||
| 10/25/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: Inflammation | ||||||
| 10/25/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.42 | General |
| 10/21/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $35.81 | General |
| 10/20/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $122.14 | General |
| 10/20/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $66.85 | General |
| 10/20/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $53.35 | General |
| 10/20/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $38.57 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects | Janssen Research & Development, LLC | $301,514 | 7 |
| A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen | Janssen Research & Development, LLC | $221,894 | 5 |
| A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Do | Janssen Research & Development, LLC | $22,438 | 7 |
| A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects | Janssen Research & Development, LLC | $19,349 | 8 |
| A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 | AbbVie Inc. | $3,038 | 9 |
| DS5565-A-E312 | Daiichi Sankyo Inc. | $2,920 | 10 |
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $666.90 | 6 |
| A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | Gilead Sciences, Inc. | $102.42 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. | Allergan Inc. | $11.12 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 53 | 5,004 | 7,901 | $444,311 | $229,512 |
| 2022 | 44 | 2,820 | 4,514 | $320,606 | $144,868 |
| 2021 | 39 | 2,407 | 3,903 | $454,523 | $147,441 |
| 2020 | 45 | 2,575 | 3,789 | $606,190 | $189,441 |
Total Patients
12,806
Total Services
20,107
Medicare Billing
$711,262
Procedure Codes
181
All Medicare Procedures & Services
181 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 182 | 345 | $103,500 | $47,464 | 45.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 173 | 354 | $76,110 | $34,022 | 44.7% |
| 87536 | Detection test by nucleic acid for hiv-1 virus, quantification | Office | 2023 | 181 | 401 | $51,328 | $33,443 | 65.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 124 | 231 | $35,805 | $14,667 | 41.0% |
| 84403 | Testosterone (hormone) level, total | Office | 2023 | 161 | 226 | $8,814 | $5,716 | 64.8% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 223 | 435 | $8,744 | $5,707 | 65.3% |
| 84402 | Testosterone (hormone) level, free | Office | 2023 | 161 | 226 | $8,814 | $5,641 | 64.0% |
| 82306 | Vitamin d-3 level | Office | 2023 | 155 | 189 | $8,505 | $5,483 | 64.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 225 | 471 | $4,239 | $3,956 | 93.3% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 147 | 206 | $5,768 | $3,712 | 64.4% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 215 | 443 | $5,626 | $3,672 | 65.3% |
| 80076 | Liver function blood test panel | Office | 2023 | 214 | 437 | $5,463 | $3,500 | 64.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $7,300 | $3,226 | 44.2% |
| 87491 | Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique | Office | 2023 | 26 | 88 | $4,664 | $3,026 | 64.9% |
| 87591 | Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique | Office | 2023 | 26 | 88 | $4,664 | $3,026 | 64.9% |
| 84270 | Sex hormone binding globulin (protein) level | Office | 2023 | 117 | 141 | $4,653 | $3,003 | 64.5% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 145 | 181 | $4,163 | $2,979 | 71.6% |
| 84481 | Thyroid hormone, t3 measurement, free | Office | 2023 | 138 | 169 | $4,310 | $2,805 | 65.1% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 151 | 180 | $6,300 | $2,660 | 42.2% |
| 83735 | Magnesium level | Office | 2023 | 203 | 398 | $4,179 | $2,615 | 62.6% |
| 83001 | Gonadotropin, follicle stimulating (reproductive hormone) level | Office | 2023 | 118 | 142 | $4,260 | $2,586 | 60.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $5,520 | $2,582 | 46.8% |
| 83002 | Gonadotropin, luteinizing (reproductive hormone) level | Office | 2023 | 118 | 142 | $4,260 | $2,577 | 60.5% |
| 82746 | Folic acid level, serum | Office | 2023 | 147 | 173 | $4,152 | $2,493 | 60.0% |
| 46601 | Diagnostic exam of anus with magnification and chemical agent enhancement using an endoscope | Office | 2023 | 20 | 20 | $9,244 | $2,179 | 23.6% |
About Dr. Peter Ruane, MD
Dr. Peter Ruane, MD is a Infectious Disease healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1467640953.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Ruane, MD has received a total of $866,043 in payments from pharmaceutical and medical device companies, with $13,456 received in 2024. These payments were reported across 1,363 transactions from 53 companies. The most common payment nature is "" ($571,934).
As a Medicare-enrolled provider, Ruane has provided services to 12,806 Medicare beneficiaries, totaling 20,107 services with total Medicare billing of $711,262. Data is available for 4 years (2020–2023), covering 181 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Los Angeles, CA
- Active Since 10/09/2007
- Last Updated 02/25/2013
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1467640953
Products in Payments
- PREZISTA (Drug) $543,816
- DOVATO (Drug) $29,412
- Epclusa (Drug) $28,154
- CABENUVA (Biological) $24,546
- RUKOBIA (Drug) $18,852
- Truvada (Drug) $18,125
- Biktarvy (Drug) $15,503
- JULUCA (Drug) $7,591
- Descovy (Drug) $6,632
- Genvoya (Drug) $5,712
- Vosevi (Drug) $4,542
- DS-5565 (Drug) $2,920
- ZEPATIER (Drug) $2,460
- MK-8591A (Drug) $2,294
- APRETUDE (Biological) $1,121
- Mytesi (Drug) $887.89
- SYMTUZA (Drug) $834.64
- PREZCOBIX (Drug) $711.46
- TRIUMEQ (Drug) $550.80
- Symtuza (Drug) $407.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Los Angeles
Dr. Jay Gladstein, M.d, M.D
Infectious Disease — Payments: $732,232
Infectious Disease $732,232
Otto Yang, Md, MD
Infectious Disease — Payments: $477,960
Infectious Disease $477,960
Irving Posalski, M.d, M.D
Infectious Disease — Payments: $235,663
Infectious Disease $235,663
Dr. Fred Sattler, M.d, M.D
Infectious Disease — Payments: $69,230
Infectious Disease $69,230
Dr. Shaker Itani, M.d, M.D
Infectious Disease — Payments: $51,940
Infectious Disease $51,940
Jim Nomura, Md, MD
Infectious Disease — Payments: $40,310
Infectious Disease $40,310